LumiraDx Limited (LMDX)
|Net Income (ttm)||-171.28M|
LumiraDx, a UK-based provider of point-of-care diagnostics including COVID-19 tests, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
LumiraDx Limited has filed to go public with an IPO on the NASDAQ.
A new rapid test for Covid-19 can return results in just 12 minutes, Health Minister Robin Swann has said.
LumiraDx Receives Authorization by Switzerlandu00b4s Federal Office of Public Health Showing Excellent Positive Agreement of its Microfluidic Antigen Test with RT-PCR for Point of Care COVID-19 Testing
LumiraDx, the next generation point-of-care diagnostic company, announced today that it has received Switzerland Federal Office of Public...
LumiraDx is a next-generation point of care, or POC, diagnostic company. We have developed and launched our LumiraDx Platform, or Platform, which is an integrated system comprised of a small, versatile POC instrument, or Instrument, precise, low-cost microfluidic test strips, and seamless, secure digital connectivity. We currently have four tests available on our Platform and a broad menu of tests in development. Our proprietary Platform is designed to simplify, scale down, and integrate multiple testing methodologies onto a single instrument a... [Read more...]
|IPO Date |
|Stock Exchange |
|Ticker Symbol |